Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could weak legs be making it hard to breathe? new study investigates

NCT ID NCT03800017

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at why people with interstitial lung disease (ILD) often feel breathless and have trouble exercising. Researchers think leg muscle problems might be a cause. They will measure leg muscle strength and structure in 40 ILD patients and test how extra oxygen affects exercise. The goal is to better understand these symptoms, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for ILD Patients: * Age 40-80 years (inclusive) * A multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF), idiopathic fibrotic nonspecific interstitial pneumonia (NSIP), chronic hypersensitivity pneumonitis (HP), or unclassifiable ILD with a differential diagnosis that consists of the above diagnoses * Fibrosis on high resolution computed tomography (HRCT): honeycombing, reticulation, or traction bronchiectasis * Appropriate candidate for pulmonary rehabilitation * 6 minute walk distance 50m or more * Oxygen saturation ≥ 92% by pulse oximetry at rest while breathing room air * Clinically stable for the preceding 6 weeks * Can fluently read and write in English Inclusion Criteria for Healthy Controls: * Age 40-80 (inclusive) * Normal pulmonary function (80-120% predicted) * No lung or cardiovascular disease * Can fluently read and write in English Exclusion Criteria for the ILD patients: * Contraindication to exercise testing (e.g. significant cardiovascular, musculoskeletal, neurological disease) * Other significant extra-pulmonary disease that, based on clinical assessment, could impair exercise capacity and/or oxygenation * Forced vital capacity (FVC) less than 50% or Diffusion capacity for carbon monoxide (DLCO) less than 25% * Concurrent or recent participation (less than 6 months) in a pulmonary rehabilitation program * Use of prednisone greater than 10 mg/day for more than 2 weeks within 3 months of the first study visit * Significant emphysema (less than 10% volume on HRCT or FEV1/FVC less than 0.70) Exclusion Criteria for Healthy Controls: * Currently smoking or previously smoked more than 10 pack-years * Any medical conditions that prevents them for exercising safely * Cardiac pacemaker or any metal or electronic inside the body

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypersensitivity pneumonitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • St. Paul's Hospital

    RECRUITING

    Vancouver, British Columbia, V6Z1Y6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.